GlassScriptPhysician profile
Garlan G Lo
NPI 1043276140
$14,608.19
in general payments reported to CMS, 2019-2025
38 companies · $1,790 in 2025
The $1,790 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $1,802 · 2021: $2,435 · 2022: $2,775 · 2023: $1,851 · 2024: $1,534 · 2025: $1,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161 · Entertainment: $13.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.24 |
| Entertainment | $13.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,957.78 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Allergan, INC. | $1,648.17 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $1,539.80 | 2022-2025 | Envista Mx60 Iol, Amvisc, Miebo |
| Alcon Vision LLC | $1,301.69 | 2019-2025 | Rocklatan, Clareon, Tryptyr |
| Aerie Pharmaceuticals, INC. | $1,113.98 | 2019-2021 | |
| Ivantis, INC | $1,071.66 | 2019-2021 | |
| Abbvie INC. | $984.82 | 2022-2025 | |
| Oyster Point Pharma, INC. | $743.01 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $466.08 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $404.94 | 2019-2023 | Tecnis Iol, Veritas Vision System, Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $391.27 | 2019-2021 | |
| Amgen INC. | $358.46 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $338.59 | 2022-2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $315.40 | 2019-2022 | |
| Sight Sciences, INC. | $307.11 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $234.06 | 2021-2025 | Oxervate |
| Beaver-Visitec International, INC. | $206.56 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $183.39 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $151.79 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $138.69 | 2021-2025 | Acthar |
| Harrow Eye, LLC | $106.48 | 2024-2025 | Vevye, Iheezo |
| Thea Pharma INC. | $101.22 | 2023-2025 | Iyuzeh |
| Shire North American Group INC | $71.10 | 2019 | |
| Ani Pharmaceuticals, INC. | $69.52 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $59.02 | 2025 | Xeomin |
| Astellas Pharma US INC | $49.71 | 2025 | Izervay |
| Coopervision INC. | $47.85 | 2022 | |
| Glaukos Corporation | $42.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.62 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $26.31 | 2023 | Syfovre |
| Ocular Therapeutix, INC. | $20.61 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Akorn, INC. | $18.41 | 2020 | |
| Biotissue Holdings INC. | $18.15 | 2022 | |
| Rxsight INC | $18.02 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Nova Eye, INC. | $14.51 | 2024 | |
| Optos, INC. | $13.66 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garlan Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.